Credits: 0.25 AMA PRA Category 1 Credit™ 

Overview: Join expert faculty as they discuss risk stratification for non-hospitalized patients with mild or moderate COVID-19 to determine who would benefit most from antiviral therapy aimed at reducing the risk of progression to severe disease. Explore national guideline recommendations on COVID-19 treatment in non-hospitalized patients, including factors to consider when selecting therapy for individual patients.